<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02243228</url>
  </required_header>
  <id_info>
    <org_study_id>XT 01</org_study_id>
    <nct_id>NCT02243228</nct_id>
  </id_info>
  <brief_title>Inhalation of Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Autoimmune Pulmonary Alveolar Proteinosis (PAP)</brief_title>
  <official_title>A Prospective Study of Inhaling Granulocyte-macrophage Colony Stimulating Factor in Adult Patients With Mild-to-moderate Autoimmune Pulmonary Alveolar Proteinosis in China: a Randomized Open-label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate if inhaled granulocyte-macrophage colony stimulating&#xD;
      factor delay the increase in alveolar-arterial oxygen difference, compared to no treatment,&#xD;
      for adult patients with mild-to-moderate autoimmune pulmonary alveolar proteinosis in China&#xD;
      over a two-year period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autoimmune pulmonary alveolar proteinosis (PAP, previously known as idiopathic PAP) is a rare&#xD;
      interstitial lung disease elicited by the formation of autoantibodies which neutralize the&#xD;
      activity of granulocyte-macrophage colony-stimulating factor (GM-CSF) which decreases&#xD;
      macrophage clearance of surfactant.&#xD;
&#xD;
      Currently, the standard treatment strategy for PAP is whole lung lavage (WLL)，which is&#xD;
      invasive and has limitations. Inhaled GM-CSF therapy became a new option for PAP patients not&#xD;
      only because of its effectiveness and safety, but it is convenient way for patients who are&#xD;
      reluctant to do operation as well. We are planning to prospectively evaluate if inhaled&#xD;
      granulocyte-macrophage colony stimulating factor would delay the increase in&#xD;
      alveolar-arterial oxygen difference (A-aDO2, which is the most sensitive factor in evaluating&#xD;
      APAP5), compared to placebo, for patients with mild-to-moderate autoimmune pulmonary alveolar&#xD;
      over a two-year period.&#xD;
&#xD;
      A total of 42 subjects with APAP who meet the inclusion criteria will be enrolled at Peking&#xD;
      Union Medical College Hospital and Nanjing Drum Tower Hospital. After observe APAP patients&#xD;
      for 3 months to rule out patients who resolved spontaneously, the participants will undergo&#xD;
      randomization (by random number table)and stratified into two different groups by their DSS.&#xD;
      Then they will be treated by GM-CSF (using nebulizer, 150ug bid) every other week or no&#xD;
      treatment for 6 months, and will be followed on an outpatient basis at 2 weeks, and 1, 3, 6,&#xD;
      9, 12, 15, 18, 21 and 24 months after initiation of therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A-aDO2 difference</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to relapse</measure>
    <time_frame>up to 2 years</time_frame>
    <description>The definition of relapse were as follow: 1) newly requirement for whole lung lavage (WLL); or 2) PAP associated death; or 3) a reduction in PaO2 of more than 10mmHg, or an increase in DA-aO2 of more than 10mmHg; or 4) a worsen chest HRCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 difference</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minutes walking distance difference</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe adverse event</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Autoimmune Pulmonary Alveolar Proteinosis</condition>
  <arm_group>
    <arm_group_label>GM-CSF, nebulizer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After the patients were randomly divided into two groups, they will be treated by GM-CSF (using nebulizer, 150ug bid) every other week for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GM-CSF</intervention_name>
    <arm_group_label>GM-CSF, nebulizer</arm_group_label>
    <other_name>HUABEI JIMUXIN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Accessible population:&#xD;
&#xD;
        Adult patients with mild-to-moderate autoimmune pulmonary alveolar and without spontaneous&#xD;
        remission will be enrolled at Peking Union Medical College Hospital and Nanjing Drum Tower&#xD;
        Hospital.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult autoimmune PAP subjects will be included: 1) a positive PAS stain from BALF or&#xD;
             lung biopsy; 2) high level of serum anti-GM-CSF antibody (&gt;2.39ug/ml, the cut-off&#xD;
             point in our hospital); 3) age above 18 years old; 4) exclude hereditary and secondary&#xD;
             PAP.&#xD;
&#xD;
          -  Able to give written informed consent and comply with the requirements of the study.&#xD;
&#xD;
          -  Patients are not eligible for the whole lung lavage (WLL), decided by clinicians.&#xD;
&#xD;
          -  Eligibility for GM-CSF inhalation: 1) Disease severity score (DSS) is 1-3; 2) No&#xD;
             treatment with GM-CSF therapy or WLLin the 3 months prior to enrollment. Definition of&#xD;
             DSS2: 1, no symptom and PaO2&gt;=70mmHg；2, PaO2&gt;=70mmHg with symptoms；3, PaO2&gt;=60 and&#xD;
             &lt;70mmHg; 4, PaO2&gt;=50 and &lt;60mmHg; 5, PaO2&lt;50mmHg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients will be observed for 3 months and all APAP patients who resolved&#xD;
             spontaneously will be excluded from our study.&#xD;
&#xD;
          -  PAP resulting from another condition (e.g. occupational exposure to silica, underlying&#xD;
             HIV, respiratory infections, myeloproliferative disorder or leukaemia);&#xD;
&#xD;
          -  A normal or low-titre serum anti-GM-CSF antibody (≤2.39ug/ml);&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions to humanized or murine monoclonal&#xD;
             antibodies；&#xD;
&#xD;
          -  Chronic lung disease associated with already existing respiratory failure (such as&#xD;
             pulmonary emphysema or fibrosis);&#xD;
&#xD;
          -  Other serious medical conditions which, in the opinion of the investigator, would make&#xD;
             the patient unsuitable for the study.&#xD;
&#xD;
          -  Pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kai-Feng Xu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hosptial</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kai-Feng Xu, M.D.</last_name>
    <phone>10-69155039</phone>
    <phone_ext>86</phone_ext>
    <email>kaifeng.xu@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xin-Lun Tian, M.D.</last_name>
    <phone>10-69155039</phone>
    <phone_ext>86</phone_ext>
    <email>xinlun_t@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai-Feng Xu, M.D.</last_name>
      <phone>10-69155039</phone>
      <phone_ext>86</phone_ext>
      <email>kaifeng.xu@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Xin-Lun Tian, M.D.</last_name>
      <phone>10-69155039</phone>
      <phone_ext>86</phone_ext>
      <email>xinlun_t@sina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xin-Lun Tian, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>September 14, 2014</study_first_submitted>
  <study_first_submitted_qc>September 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2014</study_first_posted>
  <last_update_submitted>September 16, 2014</last_update_submitted>
  <last_update_submitted_qc>September 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Kaifeng Xu</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>granulocyte-macrophage colony stimulating factor(GM-CSF)</keyword>
  <keyword>Autoimmune pulmonary alveolar proteinosis (PAP)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Alveolar Proteinosis</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

